In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $160.00. The company's shares closed last Thursday at $71.82. According to TipRanks.com, Ear is a 2-star analyst with an average return of -0.4% and a 52.4% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Avrobio, and uniQure. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $127.83 average price target. See today’s best-performing stocks on TipRanks >> The company has a one-year high of $101.
https://www.tipranks.com/news/blurbs/sarepta-therapeutics-srpt-receives-a-buy-from-mizuho-securities?utm_source=advfn.com&utm_medium=referral
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.